Capital Fund Management (CFM)
ZYNE

Capital Fund Management (CFM)’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Capital Fund Management (CFM)’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-11,775
Closed -$71K – 2137
2019
Q4 		$71K Sell
11,775
-17,725
-60% -$121K ﹤0.01% 1784
2019
Q3 		$223K Buy
+29,500
New +$332K ﹤0.01% 1551

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Capital Fund Management (CFM)'s ZYNE Position: Q1 2020 in Review

Capital Fund Management (CFM) sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2020, closing a stake of 11,775 shares — an estimated $71K sold.

Capital Fund Management (CFM) first reported a position in ZYNE in Q3 2019 and held it in 2 quarters. The position peaked at $223K in Q3 2019. 77 funds tracked by Wall St. Rank hold ZYNE as of Q1 2020.

  • Capital Fund Management (CFM) reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2020 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 11,775 Zynerba Pharmaceuticals, Inc shares in Q1 2020, an estimated $71K.
  • Capital Fund Management (CFM) first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2019 and held it in 2 quarters.
  • Capital Fund Management (CFM)'s Zynerba Pharmaceuticals, Inc position peaked at $223K in Q3 2019.
  • 77 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2020.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2020, filed 13 May 2020.